Oxford BioMedica has posted promising interim data from the Phase I/II trial of its novel gene therapy, ProSavin, for the treatment of Parkinson’s disease.

The firm says that three patients in the first-dose cohort showed improvements in disease symptoms of up to 30% at three months. An independent data monitoring committee has reviewed the results and recommended that the trial continues to evaluate the higher dose of ProSavin.

Oxford BioMedica said that there were no serious adverse events associated with ProSavin being administered directly to the striatum in the brain and all three patients were ambulatory within 48 hours of the surgical procedure. Two showed improvements in quality of life measures specific to Parkinson’s and one patient’s QoL was unchanged.

Principal investigator for the trial, Stephane Palfi from the Henri Mondor Hospital in Paris, said ProSavin has the potential to address an unmet medical need in Parkinson’s disease, “offering long-lasting benefit from a single administration”. His enthusiasm was echoed by John Dawson, acting chief executive at Oxford BioMedica, who added: "We are pleased by the progress of the first cohort of patients and we look forward to the maturing data over the coming months”.

Noting that this is the first trial using the firm’s LentiVector technology, Mr Dawson said “the preliminary safety conclusions add value not only to ProSavin, but also to our other development candidates that use the same technology". He concluded by claiming that “the favourable recommendation from the DMC to proceed to the higher dose of ProSavin is an important milestone”.

The first patient of the second cohort is expected to be treated this month and in the second stage, a further 12 patients will be recruited.